amyloid β42

Ro 90-7501 is an amyloid β42 (Aβ42) protofibrillar and TPR-dependent PP5 inhibitor, a novel radiosensitizer for cervical cancer cells, which inhibits ATM phosphorylation, promotes apoptosis, and induces cell-cycle arrest. Ro 90-7501 also exhibits antiviral activity and potential anticancer activity by inhibiting ATM phosphorylation and DNA repair, and by inhibiting HCMV.

BRI-50460 is an inhibitor of cytosolic calcium-dependent phospholipase A2 (cPLA2) with the ability to cross the blood-brain barrier, exhibiting an IC50 of 0.88 nM. By inhibiting cPLA2, BRI-50460 modulates downstream inflammatory lipid signaling pathways, mitigating the effects of amyloid β42 oligomers on cPLA2 activation, tau protein hyperphosphorylation, and synaptic and dendritic loss. This results in its activity in regulating neuroinflammation and restoring lipid homeostasis. BRI-50460 is applicable in research related to Alzheimer's disease and other neurodegenerative disorders.

Lawsoniaside can hinder the growth of amyloid-β42 fibrils.

γ-Secretase modulator 12 (Compound 1a) is a selective compound that effectively reduces amyloid-β42 (Aβ42) levels with an IC50 of 0.39 μM, specifically designed for Alzheimer's disease research. Notably, γ-Secretase modulator 12 exhibits a favorable brain plasma ratio (Kp, brain = 0.72) in mice [1].

WRW4 TFA is a formyl peptide receptor-like 1 (FPRL1) antagonist that specifically prevents the binding of WKYMVm to FPRL1 with an inhibition concentration (IC50) of 0.23 μM. It uniquely blocks the rise in intracellular calcium triggered by FPRL1 agonists such as MMK-1, amyloid beta42 (Abeta42) peptide, and F peptide [1].

2-O-Acetyl-20-hydroxyecdysone is an ecdysone present in insects and terrestrial plants. 2-O-Acetyl-20-hydroxyecdysone inhibits amyloid-β42-induced cytotoxicity and is able to reduce the formation of Aβ oligomers by promoting fibrillogenesis, which converts Aβ oligomers into less toxic fibers.